Tokyo, Japan

Yasuhito Nagai

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2015-2017

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: **Yasuhito Nagai: Innovator in 5-HT Receptor Agonist Compounds**

Introduction

Yasuhito Nagai is a prominent inventor based in Tokyo, Japan, known for his contributions to the field of pharmaceuticals. With two patents to his name, his work focuses on innovative compounds that target specific receptor-related diseases.

Latest Patents

Among Yasuhito Nagai's latest inventions is the benzazepine compound, which has been developed as an agent for treating or preventing various 5-HT receptor-related diseases. This includes conditions such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and sexual dysfunction, including erectile dysfunction syndrome. The compound also shows promise for obesity treatment. The research conducted by Nagai and his team identified compounds exhibiting excellent 5-HT receptor agonist activity, thereby contributing significantly to therapeutic options available for the mentioned health issues.

Career Highlights

Yasuhito Nagai is affiliated with Astellas Pharma GmbH, a well-respected company in the pharmaceutical industry. His work at Astellas emphasizes the integration of scientific research and innovative solutions to address pressing medical concerns.

Collaborations

Throughout his career, Yasuhito has collaborated with notable colleagues, including Hiroyuki Koshio and Norio Asai. Their combined efforts have led to advancements in pharmaceutical research, ensuring the continuous exploration of new compounds and therapeutic avenues.

Conclusion

Yasuhito Nagai's contributions to the field of pharmaceuticals, particularly through his innovative benzazepine compounds, showcase the importance of research and collaboration in tackling complex health issues. His work not only enhances the understanding of 5-HT receptor-related diseases but also opens the door for future therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…